MTPA, maker of ALS treatment Radicava, has opened up its care locator database to help patients to find healthcare and infusion centers.
Just amid a global retreat of Lartruvo, Eli Lilly's cancer portfolio suffers another setback as Verzenio runs into safety problems in Japan.
Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.
Right now, Roche’s Tecentriq is the only I-O drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile.
Innovation challenges continue to proliferate in the pharma industry, and Celgene is seeking crowdsourced solutions for multiple sclerosis patients.
With increasing numbers of novel biopharma platforms vying for a voice and money, it's more difficult for investors to assign them proper values.
The Cannes Lions Health pharma jury is now set, with the group set to meet in France for the festival and awards June 17 and 18.
AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.
Ionis has a long-standing reputation for being science driven, but in its 30-year history the company had never told its own story—until now.
Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun, Mexico.
